EASD 2019: The DEFINE-HF trial - Dr Mikhail N Kosiborod

 

Dr Mikhail N Kosiborod (Saint Luke's America Heart Institute, Kansas City, US) discusses the DEFINE-HF trial - Dapagliflozin effects on biomarkers, symptoms and functional status in HFrEF patients with or without diabetes.

 

Filmed on site at EASD 2019 by Radcliffe Cardiology.